A therapeutic humanized anti-HER3 antibody (EV20) conjugated through a cathepsin-cleavable linker to the DNA minor groove-binding agent NMS-P528, was shown to be effective in a variety of xenograft models, including pancreatic cancer [49]. Here, ERBB3 is linked to pancreatic neoplasm.